Frontiers in Pharmacology · 2019 · 22 citations · 20 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer Drug DeliveryNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsActive Tumor TargetingBiodistribution StudiesChemical ModificationDrug-delivery ApplicationsIron Oxide NanoparticlesMagnetic Nanoparticle Drug CarriersNanoparticle DeliveryTumor-targeted Drug Delivery
Superparamagnetic iron-oxide nanoparticle (SPION) has gained tremendous attention for drug delivery applications due to their unique properties. In this study, we developed a dual targeted delivery system with paclitaxel (PTX) and SPION co-loaded PLGA nanoparticles which was modified with Pep-1 peptide (Pep-NP-SPION/PTX), aiming to achieve magnetic targeting and active targeting for tumor treatment. SPION was synthesized by a co-precipitation method and was then encapsulated with PTX simultaneously into PLGA nanoparticles. After that, the noncomplex was conjugated with Pep-1 through chemical modification. The resulting Pep-NP-SPION/PTX showed a spherical morphology and an average size around 100 nm. The enhancement cellular uptake of Pep-NP-SPION was demonstrated in in vitro by cell experiment. The IC50 value of Pep-NP-SPION/PTX and NP-SPION/PTX was determined to be 10.2 μg/mL and 19.4 μg/mL, respectively. Biodistribution study showed that obviously higher accumulation of Pep-NP-SPION was observed in tumor compared with that of non-targeting nanocomposite. Moreover, under the condition of magnetic field, both NP-SPION and Pep-NP-SPION exhibited much higher tumor distribution. Furthermore, Pep-NP-SPION/PTX presented desirable in vivo anti-tumor effect based on the active targeting and magnetic targeting characteristics. Taken together, Pep-NP-SPION/PTX could offer a magnetic targeting and receptor mediated targeting to enhance the anti-tumor outcome.
20
Koji Kawakami, Jun Taguchi, Takashi Murata et al. · Blood · 2001 · 216 citations · Full text
A Folate Receptor-Targeting Nanoparticle Minimizes Drug Resistance in a Human Cancer Model
Xu Wang, Jun Li, Yuxiang Wang et al. · ACS Nano · 2011 · 143 citations
Pharmacy, Oncology, Pharmacology +17
IL-13Rα2 is a Glioma-Restricted Receptor for Interleukin-13
Akiva Mintz, Denise M. Gibo, Becky Slagle‐Webb et al. · Neoplasia · 2002 · 141 citations · Full text
Medicine, Immunology, Oncology +10